Details

Autor(en) / Beteiligte

• Kojima, Machiko
• Sone, Kenbun
• Oda, Katsutoshi
• Hamamoto, Ryuji
• Kaneko, Syuzo
• Oki, Shinya
• Kukita, Asako
• Kawata, Akira
• Honjoh, Harunori
• Kawata, Yoshiko
• Kashiyama, Tomoko
• Sato, Masakazu
• Taguchi, Ayumi
• Miyamoto, Yuichiro
• Tanikawa, Michihiro
• Tsuruga, Tetsushi
• Nagasaka, Kazunori
• Wada-Hhraike, Osamu
• Osuga, Yutaka
• Fujii, Tomoyuki

Titel

The histone methyltransferase SMYD2 is a novel therapeutic target for the induction of apoptosis in ovarian clear cell carcinoma cells

Ist Teil von

• Oncology letters, 2020-11, Vol.20 (5), p.1-1

Ort / Verlag

Athens: Spandidos Publications

Erscheinungsjahr

2020

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• Previous studies have suggested that histone methylation can modulate carcinogenesis and cancer progression. For instance, the histone methyltransferase SET and MYND domain containing 2 (SMYD2) is overexpressed in several types of cancer tissue. The aim of the present study was to determine whether SMYD2 could serve a therapeutic role in ovarian clear cell carcinoma (OCCC). Reverse transcription-quantitative PCR was used to examine SMYD2 expression in 23 clinical OCCC specimens. Moreover, OCCC cell proliferation and cell cycle progression were also examined following small interfering RNA-mediated SMYD2 silencing or treatment with a selective SMYD2 inhibitor. SMYD2 was significantly upregulated in clinical OCCC specimens, compared with normal ovarian tissue. In addition, SMYD2 knockdown decreased cell viability as determined via a Cell Counting Kit-8 assay. Moreover, the proportion of cells in the sub-[G.sub.1] phase increased following SMYD2 knockdown, suggesting increased apoptosis. Treatment with the SMYD2 inhibitor LLY-507 suppressed OCCC cell viability. These results suggested that SMYD2 could promote OCCC viability, and that SMYD2 inhibition induced apoptosis in these cells. Thus, SMYD2 inhibitors may represent a promising molecular targeted approach for OCCC treatment. Key words: histone methyltransferase, SMYD2, ovarian clear cell carcinoma, epigenetic modification, SMYD2 selective inhibitor